Memory Pharmaceuticals Corp. (MEMY) is in the Pharma Industry

• Sort by

• Memory Pharmaceutical Q4 2007 Earnings Call Transcript

  Memory Pharmaceutical Q4 2007 Earnings Call Transcript

  Earnings calls 2008-03-19

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Memory Pharmaceuticals Corp.

Additional Resources

• Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute

  - Results in Proceeds of $2.0 Million - MONTVALE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007 equity financing...

  Articles 2008-08-26

• Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008

  MONTVALE, N.J., July 30 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease ICAD in Chicago. The results demonstrate that MEM 68626 is effective in models of cognition...

  Articles 2008-07-30

• Memory Pharmaceuticals Closes Second Tranche of Equity Financing with The Stanley Medical Research Institute

  - Results in Proceeds of $2 Million - MONTVALE, N.J., June 24 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has secured $2 million through the sale of approximately 4.7 million shares of common stock under its equity financing agreement with an...

  Articles 2008-06-24

• Investigate Emerging Diagnostic Technologies for Use in Psychiatric Indications

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/fc91d1/emerging_diagnosti) has announced the addition of Decision Resources, Inc.'s new report "Emerging Diagnostic Technologies for Use in Psychiatric Indications" to their offering. Introduction The diagnosis of psychiatric diseases is an inexact science and a slow process for...

  Articles 2008-06-18

• Now In Its Fourth Year, 'The CNS Market 2008 Report' Is an Expanded and Updated 400 Page Report of Brain and Nervous System Markets and Treatments

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/ab0827/the_cns_market_200) has announced the addition of the "The CNS Market 2008 Report" published by NeuroInsights to their offering. Drugs, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease...

  Articles 2008-06-12

• Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter

  - Company to Request a Hearing - MONTVALE, N.J., June 9 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that on June 6, 2008 it received a letter from the NASDAQ Listing Qualifications Department notifying the Company that, because it has not regained compliance...

  Articles 2008-06-09

• Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

  MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. ...

  Articles 2008-05-16

• Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

  MONTVALE, N.J., May 14 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today reported its financial results for the first quarter ended March 31, 2008. "We had a productive start to 2008, reporting significant progress with our collaborations and refocusing our operations to advance four high-value programs," said Vaughn...

  Articles 2008-05-14

• Memory Pharmaceuticals to Host R&D Day on May 16, 2008

  MONTVALE, N.J., May 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. , today announced that it will host an R&D Day for the investment community on Friday, May 16, 2008 in New York City. Presentations will begin at 9:00 a.m. EDT and will focus on the Company's progress with its nicotinic...

  Articles 2008-05-12

• Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008

  MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during a conference...

  Articles 2008-05-07

• Memory Pharmaceuticals Corp. Changes and Reallocates Programs.

  M2 PRESSWIRE-12 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Changes and Reallocates ProgramsC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have...

  Articles 2008-03-12

• Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

  -Expands PDE10 Collaboration with Amgen- -Company to Host Conference Call at 9:00 A.M. EDT- MONTVALE, N.J., March 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has realigned its operations, reallocated its resources and extended the preclinical research portion of its PDE10 collaboration...

  Articles 2008-03-12

• Has added Memory Pharmaceuticals Corp. to their watch list.

  M2 PRESSWIRE-12 March 2008-The Maybach Review: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...

  Articles 2008-03-12

• Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end Results.

  M2 PRESSWIRE-7 March 2008-NASDAQNEWS: Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end ResultsC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world...

  Articles 2008-03-07

• Has added Memory Pharmaceuticals Corp. to their watch list.

  M2 PRESSWIRE-7 March 2008-MG Strategies: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers, researchers,...

  Articles 2008-03-07

• Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

  - Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 - MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system...

  Articles 2008-03-06

• Global Market Review on Memory Pharmaceuticals Corp.

  M2 PRESSWIRE-6 March 2008-Market Review: Global Market Review on Memory Pharmaceuticals Corp.C1994-2008 M2 COMMUNICATIONS LTD RDATE:06032008 Streetinvesting.com has now resumed our progressive review of Memory Pharmaceuticals Corp. (Nasdaq: MEMY) after it traded down 8% Thursday, late in the morning...

  Articles 2008-03-06

• Has added Memory Pharmaceuticals Corp. to their watch list.

  M2 PRESSWIRE-29 February 2008-NASDAQNEWS: Has added Memory Pharmaceuticals Corp. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:29022008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate....

  Articles 2008-02-29

• Progressive Review for Memory Pharmaceuticals Corp.

  M2 PRESSWIRE-28 February 2008-Market Review: Progressive Review for Memory Pharmaceuticals Corp.C1994-2008 M2 COMMUNICATIONS LTD RDATE:28022008 Streetinvesting.com has now resumed our progressive review of Memory Pharmaceuticals Corp. (Nasdaq: MEMY) after it traded unchanged Thursday, early in the afternoon with below...

  Articles 2008-02-28